Literature DB >> 20140681

Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression.

Christopher S Bryant1, Adnan R Munkarah, Sanjeev Kumar, Ramesh B Batchu, Jay P Shah, Jeremy Berman, Robert T Morris, Zhong L Jiang, Ghassan M Saed.   

Abstract

PURPOSE: The goal of this study was to investigate the effects of silencing HIF-1 alpha gene expression with specific small interfering RNA (siRNA) on VEGF production and angiogenesis in epithelial ovarian cancer (EOC) cells.
METHODS: Two EOC cell lines, MDAH-2774 and SKOV-3, were cultured under normoxic (20% O(2)) and hypoxic (2% O(2)) conditions using standard techniques. After EOC cells were transfected with siRNA, HIF-1 alpha and VEGF mRNA levels were measured by real-time RT-PCR. Angiogenesis was evaluated utilizing an in vitro assay model consisting of human umbilical vein endothelial cells (HUVEC) and polymerized ECM Matrix.
RESULTS: Both EOC cell lines evaluated constitutively expressed HIF-1 alpha and VEGF mRNA. HIF-1 alpha and VEGF mRNA levels were significantly increased in response to hypoxia (P < 0.05). Under hypoxic conditions, inhibition of HIF-1 alpha gene expression by a specific siRNA resulted in a significant reduction in HIF-1 alpha and VEGF mRNA levels (P < 0.05). In the in vitro angiogenesis model, supernatant from the hypoxic EOC cells induced the HUVEC to form a complex tubular network, a hallmark of angiogenesis. Semi-quantitative analysis of the angiogenesis assay revealed a significant reduction in tube formation when supernatant from HIF-1 alpha siRNA-treated hypoxic EOC cell was used (P < 0.05).
CONCLUSION: Inhibition of HIF-1 alpha expression by specific siRNA resulted in a significant decrease in VEGF production and angiogenesis. Further investigation of HIF-1 alpha inhibition for anti-tumor activity is warranted and may potentially prove HIF-1 alpha as a therapeutic target in the management ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140681     DOI: 10.1007/s00404-010-1381-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies.

Authors:  Parvin Ataie-Kachoie; Mohammad H Pourgholami; Farnaz Bahrami-B; Samina Badar; David L Morris
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 2.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

3.  Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  BMC Med       Date:  2012-01-26       Impact factor: 8.775

4.  Prostate cancer cell lines under hypoxia exhibit greater stem-like properties.

Authors:  Yuanyuan Ma; Dongming Liang; Jian Liu; Karol Axcrona; Gunnar Kvalheim; Trond Stokke; Jahn M Nesland; Zhenhe Suo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

Review 5.  Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview.

Authors:  Amir Abbas Hamidi; Ghazaleh Khalili-Tanha; Zahra Nasrpour Navaei; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2022-02-10       Impact factor: 5.722

Review 6.  Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.

Authors:  Madison Pereira; Kathy Matuszewska; Colin Jamieson; Jim Petrik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

7.  Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia.

Authors:  Monika Englert-Golon; Małgorzata Tokłowicz; Aleksandra Żbikowska; Stefan Sajdak; Małgorzata Kotwicka; Mirosław Andrusiewicz
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

Review 8.  The "Sweet Spot" of Targeting Tumor Metabolism in Ovarian Cancers.

Authors:  Katelyn Tondo-Steele; Karen McLean
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

Review 9.  Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages.

Authors:  Martin J Cannon; Debopam Ghosh; Swetha Gujja
Journal:  Vaccines (Basel)       Date:  2015-05-29

Review 10.  Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes.

Authors:  Yae Chan Song; Seung Eon Lee; Young Jin; Hyun Woo Park; Kyung-Hee Chun; Han-Woong Lee
Journal:  Mol Cells       Date:  2020-09-30       Impact factor: 5.034

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.